Long-term intravenous infusion of antiarrhythmic drugs using a totally implanted drug delivery system by Anderson, Jeffrey L. et al.
Long-Term Intravenous Infusion of Antiarrhythmic Drugs 
Using a Totally Implanted Drug Delivery System 
JEFFREY L. ANDERSON, MD, FACC’ 
ELTON M. TUCKER+ 
STANISLAW PASYK, MD 
EUGENE PATTERSON, PhD 
ARTHUR B. SIMON, MD, FACC 
WILLIAM E. BURMEISTER 
BENEDICT R. LUCCHESI, PhD, MD 
BERTRAM PITT, MD, FACC 
with the technical assistance of 
RICHARD P. DONAHUE 
MARILYN E. CONLON, MA 
Ann Arbor, Michigan 
From the Department of Internal Medicine, Divi- 
sion of Cardiology and the Department o! Phar- 
macology, University of Michigan School’ of 
Medicine and from The Upjohn Center for Clinical 
Pharmacology, Ann Arbor, Michigan. Manuscript 
received August 18, 1981; revised manuscript 
received December 9, 198 1, accepted December 
10, 1981. 
+ lnfusaid Corporation, Sharon, Massachu- 
setts. 
Recently, an implantable drug delivery system (Infusaid Corporation, 
Sharon, Massachusetts) has become available for long-term delivery of 
selected drugs.5-s Recent applications have included administration of 
such diverse drugs as heparin, insulin and cancer chemotherapeutic 
agents. Use of the pump in patients for up to 4 years has now been 
achieved. The Infusaida pump consists of a hollow titanium disk sepa- 
rated into two compartments by a metal bellows (Fig. 1). The pump is 
powered by the vapor pressure of a two phase charging fluid in equilib- 
rium with its liquid phase at body temperature. The pressure exerted 
on the bellows forces the drug from the reservoir at a constant rate 
through a filter and fine bore catheter into a delivery site (that is, pe- 
ripheral vein). The drug reservoir is refilled percutaneously through a 
port by means of a hypodermic syringe. We sought to establish the fea- 
sibility of long-term parenteral delivery of selected antiarrhythmic drugs 
using this totally implantable pump system. 
l Current address and address for reprints: Methods 
Jeffrey L. Anderson, MD, University oi‘lJtah 
Medical School, C/O LDS Hospital, pivision of 
Cardiology, 325 Eighth Avenue, Salt Lake City, 
Utah 84143. 
In vitro and in vlvo testing was performed to establish the feasibility of a 
totally implantable pump system to deliver antiarrhythmic agents. In vitro 
flow characteristics suggested predictable day to day delivery with ac- 
ceptably small variations in flow with changes in reservoir volume or 
temperature. During 3 months of in vitro testing, procainamide and 
bretylium were found suitable for long-term delivery. Delivery of lidocaine 
was limited by high viscosity and corrosion of steel elements within the 
pump. The pump was implanted in a subcutaneous pocket in four dogs. 
Procainamide (0.5 g/ml), delivered at 4 ml/day (70 mg/kg body weight 
per day), provided a mean steady state drug concentration of 5.3 pg/ml. 
Wetylium (50 mg/ml), delivered at 8 ml/day (13 mg/kg per day), provided 
a steady state concentration of 0.8 pg/ml (range 0.4 to 1.4). Long-term 
intravenous administration of therapeutic doses of bretyllum and pro- 
cainamide with this delivery system has been demonstrated in dogs and 
appears to be feasible in human subjects. 
Successful antiarrhythmic therapy depends on the maintenance of 
therapeutic concentrations of a drug in blood and myocardium.1>2 
However, long-term oral treatment with several antiarrhythmic agents 
is limited by unfavorable pharmacodynamics. Bretylium, for example, 
is poorly absorbed when administered orally.3y4 Lidocaine is subject to 
extensive hepatic first pass degradation, limiting its use to intravenous 
administration.2 Procainamide has a short plasma half-life (about 3 
hours), requiring frequent dosing-for maintenance of therapeutic con- 
centrations. Because of these considerations, the effective use of these 
and similar agents has been limited primarily to hospitalized patients 
receiving intravenous medication under careful monitoring in the in- 
tensive care unit. 
The study included in vitro and in vivo testing of the drug delivery system. 
Antiarrhythmic agents selected for testing included lidocaine, procainamide 
and bretylium tosylate. 
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FIGURE 1. Schematic diagram of metal bellows pump 
BELLOWS 
system (Infusai~, model 100). Courtesy lnfusaid Cor- 
poration, Sharon, Massachusetts. 
Pump characteristics: The design and performance 
characteristics of the pump are summarized in Table I. Pumps 
with a reservoir volume of both 60 and 35 ml were used. The 
flow rate of the pump is adjusted at the factory and was set at 
6 to 12 ml/day of water for this study. Output pressure is 450 
mm Hg at 37O C. The dimensions and weight of the larger unit 
are given in Table I. The materials in contact with the drug 
used in the unit include titanium, stainless steel, polypro- 
pylene, silicone rubber and a membrane filter. 
In vitro testing with water or saline solution: Such 
testing was initially performed to establish flow characteristics 
with respect to time, temperature and reservoir volume. The 
reliability of long-term in vitro delivery and compatibility of 
selected drugs with pump elements were tested during a 3 
month period. Functioning pumps were disassembled after 
3 months and inspected microscopically for evidence of cor- 
rosion or material fatigue. 
Lidocaine viscosity measurements were made separately 
using a Cannon-Fenske capillary viscometer. Measurements 
at 21° C were made in ambient air; those at 39O C were con- 
ducted in a water bath. Samples were equilibrated for at least 
20 minutes before measurement. 
Surgical implantation:‘The pump was next implanted in 
a subcutaneous abdominal pocket in each of four dogs for in 
vivo testing. Surgical implantation of the pump was similar 
to placement of a relatively large pacemaker unit. A subcu- 
taneous pocket was fashioned in the right lower abdominal 
area into which the pump ‘was placed and anchored. An inci- 
sion was made over the femoral triangle, and the delivery 
catheter, tunneled from the subcutaneous pocket, was inserted 
into the femoral vein and advanced about 20 cm. The pump 
was anchored and the abdominal pocket closed in layers. 
Prophylactic antibiotic agents (penicillin, streptomycin) were 
administered and the pocket allowed to heal. 
In vivo feasibility studies: Such studies for the three drugs 
were performed successively in the four dogs. Lidocaine de- 
livery was tested over 24 to 48 hours (four studies). The de- 
livery of procainamide (three studies) and bretylium (five 
studies) was tested for 2 week periods. Studies were initiated 
by replacement of saline solution in the pump reservoir with 
lidocaine hydrochloride (0.04,0.35 and 0.70 g/ml), procain- 
amide hydrochloride (0.5 g/ml) or bretylium tosylate (50 
mg/ml). The pump was refilled every 2 to 7 days (average 3) 
as required by individual pump delivery rates and reservoir 
volumes. During refilling, the conscious dog was restrained 
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Hubner point needle inserted through the skin and pump- 
inlet septum. Residual pump volume was measured and the 
pump filled with drug. 
Plasma blood concentrations: Blood samples were 
withdrawn from a forearm vein generally at 1,2,8,24 and 48 
hours; every 1 to 2 days during the testing period (usually 2 
weeks); and on washout days 1 and 2 after replacement of drug 
with normal saline solution. Plasma was assayed for lidocaine 
and procainamide in the clinical pharmacology laboratory 
with use of standard methods. Bretylium was assayed using 
a method developed in our institution.g 
Results 
In vitro testing: Pump flow was predictably influenced by 
bath temperature and variations in spring force of the metal 
bellows as the reservoir moved from full to empty. During in 
vitro testing, flow rose linearly by 6 percent per degree Fahr- 
enheit elevation in temperature about the physiologic range 
(95 to 103” F) (35 to 39.4“ C). In vivo flow depends on body 
temperature, which is closely regulated. Over the useful range 
of reservoir volumes, flow variability was consistently f3 to 
5 percent (coefficient of variation) about the mid range vol- 
ume. A typical result of in vitro testing over 22 days (pump 
S/N 029) consisted of a mean (f standard deviation) delivery 
rate of 6.15 (f0.34) ml/day (20 determinations). Overfilling, 
associated with increased output, and reservoir depletion 
below residual volume, associated with decreased output, were 
easily avoided. 
TABLE I 











Empty weight (g) 
Materials 
50 (47. useful volume) 
Adjusted at factory to desired value 
4i$pic8y0& at 6 to 12) 
df 
180 
Drug in contact with titanium, stainless 
steel, polypropylene, silicone rubber 
and a membrane filter 
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FIGURE 2. Viscosity of lidocaine solutions (in centipoise [CP]) as a 
function of concentration (Cont.) (percent = g/ml X 100) at two tem- 
peratures bounding the physiologic range. 
During 3 months of in vitro testing, the pump delivered 
procainamide and bretylium reliably with continuous capillary 
flow (4 and 8 ml/day, respectively) and normal filter function. 
No evidence of element corrosion or reservoir precipitate was. 
noted. 
In contrast, lidocaine caused galvanic corrosion of stainless 
steel elements within the pump. An additional problem with 
lidocaine is shown in Figure 2. Over the concentration range 
of 35 to 70 percent (g/ml), calculated to result in therapeutic 
drug delivery, a steep rise in viscosity occurred and samples 
acted as saturated solutions. 
In vivo studies: The results of in vivo studies for the three 
drugs are presented in Figure 3. Therapeutic ranges in pa- 
tients are overlaid for comparison. 
Average systemic concentrations of Eidocaine of only 0.1 
pglml were achieved. The range of individual steady state 
determinations during lidocaine infusions was 0 to 24 ng/ml 
(mean 6 ng/ml, n = 7) for the 4 percent solution and 27 to 139 
ng/ml (mean 82 ng/ml, n = 13) for solutions of 35 to 70 percent. 
Simultaneous concentrations of the lidocaine metabolites 
glycinexylidide and monethylglycinexylidide were also low 
(mean value 32 and 16 ng/ml, respectively; 35 to 70 percent 
lidocaine solutions). The low lidocaine concentrations may 
be ascribed, at least in part, to high drug viscosity and adverse 
pump-drug interactions which were noted during in vitro 
testing. 
Results with procainamide and bretylium were more fa- 
vorable. A commercial preparation of procainamide (0.5 g/ml) 
infused at 4 ml/day allowed delivery of 70 mglkg per day. 
Steady state concentrations of procainamide within the 
therapeutic range were attained, with a mean plasma con- 

















FIGURE 3. Average systemic concentrations attained during in vivo 
testing of three antiarrhythmic drugs: lidocaine (Lido), procainamide 
(PCA) and bretylium tosytate @ret). See text for details. The therapeutic 
ranges for patients of these drugs are overlaid in the shaded bars for 
comparison. The bars indicate the mean concentration attained for each 
drug. 
reached by 8 to 24 hours. The range of individual determina- 
tions was 3.4 to 8.0 pg/ml during tests in three dogs; the 
coefficients of variation during tests lasting 2 weeks averaged 
15 percent. 
Delivery of bretylium at 13 to 15 mg/kg per day provided 
mean steady state concentrations of 0.79 pglml during five 
experiments in four dogs (range of means, 0.39 to 1.39). These 
values fall within the preliminary therapeutic plasma range 
of 0.5 to 1.5 pg/m1.3Jo The range of all individual steady state 
values was 0.26 to 1.83 pg/ml. In vitro delivery rates, estimated 
to within f0.5 ml/day, averaged 8.4 (f1.0) ml/day (coefficient 
of variation = 12.3 percent, for all experiments). Steady state 
concentrations were attained by 24 hours. 
Figure 4 shows a representative experiment with bretylium 
in one dog. The pump is filled with bretylium tosylate on day 
0, and a rapid rise in serum drug concentration occurs over 8 
hours. Steady state concentrations of 400 f 100 ng/ml are 
provided over 14 days by delivery of 8 ml/day. After evacua- 
tion of the drug from the pump on day 14 and replacement 
with normal saline solution, elimination of bretylium from 
serum occurs over 2 to 3 days. Variations in in vivo plasma 
drug concentrations (coefficient of variation = 19 percent) and 
flow rates (coefficient of variation = 17 percent) were greater 
than variations in in vitro delivery rates (coefficient of vari- 
ation = 5 percent) but small enough to maintain constant 
therapeutic drug concentrations. Similar in vivo variations 
in determinations of partial thromboplastin time have been 
noted during delivery of heparin.7 Systemic effects of brety- 
lium were apparent in each dog, as evidenced by relaxation 
of the nictitating membrane of the eye, a manifestation of the 
sympathetic neuronal blocking effects of the drug. No other 
drug reactions were noted. 
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FIGURE 4. In vitro delivery of bretylium shown for a 
representative experiment in a single dog. The plasma 
concentration of bretylium @g/ml) is plotted against time t 1 ? I I ? I 1 t 1 1 t 1 I ttNS! I 
(davs). Arrows indicate the time of oumo evacuation and 0 I 2 345678 9 IO II 12 13 I4 I5 I6 
;efilling. NS = normal saline solution. ’ 
Discussion 
Long-term delivery of drugs from a subcutaneous 
reservoir is not a new idea; however, the use of sophis- 
ticated implantable infusion devices has undergone 
extensive development only in recent years.8 The im- 
plantable pump used in these studies was initially de- 
signed and tested at the University of Minnesota by 
Blackshear and colleagues5,6 in the early 1970s. Reliable 
delivery of intravenous heparin at rates of 2 to 5 ml/day 
was subsequently demonstrated in dogs for periods of 
1 to more than 4 years. 7,8 The pump was successfully 
used for long-term heparin delivery in a small number 
of patients for periods of up to 4 years in reported trials 
by the same group.8 Reliable delivery of various che- 
motherapeutic agents selectively into the hepatic ar- 
terial system in patients with a liver tumor and into the 
cerebrospinal fluid in patients with advanced malig- 
nancy of the central nervous system was recently dem- 
onstrated.sJ1J2 Other early investigational applications 
of the pump include delivery of insulin in diabetic pa- 
tients and selective delivery of neuropharmaceutical 
agents.8 
Advantages: Advantages of the pump system, as 
suggested by this and previous studies, include: (1) total 
implantability, which diminishes the problems of in- 
fection and disruption present with partially implanted 
units; (2) a permanent, nondepletable natural (thermal) 
power system; (3) simple refilling requirements; (4) 
relatively large reservoir capacities; and (5) compati- 
bility with a large number of drugs. The future inte- 
gration of a sensing circuit and programmable flow-rate 
systems with the delivery pump should further increase 
the sophistication and utility of this and other pump 
systems currently under development. 
Application to antiarrhythmic drug adminis- 
tration: New approaches to antiarrhythmic therapy are 
needed to reduce the incidence of sudden cardiac 
death.13 In part, failure of ant&u-rhythmic therapy is due 
to failure to deliver effective agents reliably and con- 
tinuously. Treatment with such standard agents as 
DAY 
lidocaine, procainamide and bretylium is limited by 
their specific pharmacodynamic properties.lr2 Lidocaine 
is ineffective when given orally because of extensive first 
pass hepatic metabolism. Procainamide must be given 
every 3 to 4 hours because of its short (3 hour) half-life; 
poor patient compliance with failure of arrhythmia 
control commonly results. Bretylium, a potent antifi- 
brillatory drug, appears to be of limited use as an oral 
agent because of poor absorption (20 percent bioavail- 
ability).3,4 The present study demonstrated a method 
of delivering therapeutic concentrations of bretylium 
and procainamide in dogs and suggests the feasibility 
of this technique in patients. Although therapeutic 
concentrations of lidocaine were not attained, they may 
be possible with further work, including further modi- 
fication of pump materials and design to address 
problems of incompatibility and high drug viscosity. 
The delivery of therapeutic concentrations of pro- 
cainamide may prove more challenging in human 
beings than in dogs. Flow rates of 12 ml/day will prob- 
ably be required. This could be attained with pumps 
adjusted to higher flow rates, requiring refilling every 
3 to 4 days. It is unlikely that solutions of procainamide 
more concentrated than the relatively viscous 0.5 g/ml 
solution will be useful. Gradual oxidation of procain- 
amide solution occurs with time, imparting a yellow 
color but without affecting the assayed concentration 
of the parent drug. 
Of the three drugs tested, bretylium appears to be 
best suited for long-term pump delivery. Its high sol- 
ubility and low viscosity also suggest that it may be 
administered to patients in even more concentrated 
solutions (100 to 150 mg/ml), which should provide 
systemic drug levels equal to or exceeding those attained 
in dogs. In contrast, patients treated with oral bretylium 
in three-fold greater dosages (40 mg/kg per day) attain 
steady state concentrations of drug of only 0.2 pug/ml, 
one fourth of the therapeutic values achieved by our 
pump infusions. 
Bretylium is indicated for acute intravenous therapy 
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of malignant ventricular arrhythmias refractory to 
standard treatment. Currently, administration of the 
drug must be discontinued after 3 to 5 days for want of 
an effective mode of long-term therapy. Bretylium is the 
only currently available class III (antifibrillatory) agent 
approved for general use in the United States. Thus, 
patients who are prone to recurrence of arrhythmias 
that respond to bretylium may be benefited by the op- 
portunity for effective long-term drug delivery with a 
totally implanted pump system. 
Implications: Favorable experience with the im- 








vestigations with other cardiovascular drugs. These 
might include selected inotropic agents, vasodilators 
and anticoagulant drugs, in addition to antiarrhythmic 
agents. 
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